North American Report

Schizophrenia pipeline possesses potential drugs in mid stage developments to be launched in the upcoming years

 Breaking News
  • No posts were found

Schizophrenia pipeline possesses potential drugs in mid stage developments to be launched in the upcoming years

July 07
00:37 2021
Schizophrenia pipeline possesses potential drugs in mid stage developments to be launched in the upcoming years

Schizophrenia Market
The growing prevalence of Schizophrenia patients in the 7MM market has resulted in an increase in Schizophrenia market size.

DelveInsight’s Schizophrenia market report provides an in-depth understanding of Schizophrenia, historical and forecasted epidemiology, and Schizophrenia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Some of the Crucial Highlights from the Schizophrenia Market Report

  • As per DelveInsight Schizophrenia epidemiology insights, the total prevalent population was observed to be 5,748,062 in 7MM in 2020.

  • In 2020, the Schizophrenia diagnosed prevalent population was over 3 million in 7MM.

  • Among the EU5 countries, Germany has the highest Schizophrenia diagnosed prevalent population while Spain had the lowest in 2020.

  • Men had the majority of Schizophrenia cases than women in the US and EU5, but had a lesser number of Schizophrenia cases in Japan as compared to women in 2020.

  • Schizophrenia pipeline drugs include Doria (risperidone ISM) (Rovi Pharmaceuticals Laboratories), Roluperidone (Minerva Neurosciences), Dexmedetomidine (BXCL501) (BioXcel Therapeutics), SEP363856 (Sunovion/PsychoGenics), Pimavanserin (Acadia Pharmaceuticals), ALKS 3831 (Alkermes), Avisetron (AVN-211) (Avineuro Pharmaceuticals), BI 409306 (Boehringer Ingelheim), GWP42003-P (GW Research), KarXT (Karuna Pharmaceuticals), Evenamide (Newron Pharmaceuticals), Paliperidone Palmitate 6-Month(PP6M) (Janssen Pharmaceutical) and others.

  • Key pharmaceutical companies such as Rovi Pharmaceuticals Laboratories, Minerva Neurosciences, BioXcel Therapeutics, Sunovion/PsychoGenics, Acadia Pharmaceuticals, Alkermes, Avineuro Pharmaceuticals, Boehringer Ingelheim, GW Research, Karuna Pharmaceuticals, Newron Pharmaceuticals, Janssen Pharmaceutical, and others are developing therapies for Schizophrenia treatment.

To find out more about schizophrenia, request sample @ Schizophrenia Market

The Schizophrenia market report covers current treatment methods, developing medications, and market share of specific therapies, as well as the current and predicted market size of Schizophrenia in 7MM from 2018 to 2030. To gather the best of the opportunities and assess the underlying potential of the industry, the report also examines existing Schizophrenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs.

Schizophrenia: Overview

Schizophrenia is a severe mental illness that impairs one’s capacity to think effectively, manage emotions, make decisions, and interact with others. It’s a long-term medical condition that affects roughly 1% of the population of the United States. Schizophrenia is produced by a complex interplay of genetics and environmental circumstances, rather than by a single genetic mutation. While Schizophrenia affects 1% of the population, having a family history of psychosis considerably increases the risk.

Schizophrenia Epidemiology Segmentation

  • Schizophrenia Prevalent Cases

  • Schizophrenia Diagnosed Prevalent Cases

  • Schizophrenia Gender-Specific Diagnosed Prevalent Cases

  • Schizophrenia Age-Specific Diagnosed Prevalent Cases

  • Schizophrenia Severity-Specific Diagnosed Prevalent Cases

Schizophrenia Treatment Landscape

Antipsychotics are the most common drugs used to treat Schizophrenia. They are often useful in treating positive Schizophrenia symptoms. Antipsychotic drugs affect everyone differently, so a patient may need to try many before finding the one that works best for them. The major options for Schizophrenia treatment include:

  • Risperdal (risperidone)

  • Abilify (aripiprazole)

  • Invega Trinza/sustenna

  • Rexulti (brexpiprazole)

  • Latuda (lurasidone hydrochloride)

  • Caplyta (lumateperone)

Schizophrenia Market

As per DelveInsight, the Schizophrenia market size was estimated to be USD 7,454.97 million in 7MM in 2020. The prevalence of Schizophrenia patients in the 7MM market is increasing, resulting in a larger Schizophrenia market. Patients and physicians have a high degree of information regarding the symptoms, diagnosis, treatment, and management of Schizophrenia due to the availability of healthcare resources. This will contribute to the future growth of the Schizophrenia market.

Get more insights about schizophrenia management @ Schizophrenia Drugs

Schizophrenia Pipeline Therapies and Key Companies

  • Doria (risperidone ISM): Rovi Pharmaceuticals Laboratories

  • Roluperidone: Minerva Neurosciences

  • Dexmedetomidine (BXCL501): BioXcel Therapeutics

  • SEP363856: Sunovion/PsychoGenics

  • Pimavanserin: Acadia Pharmaceuticals

  • ALKS 3831: Alkermes

  • Avisetron (AVN-211): Avineuro Pharmaceuticals

  • BI 409306: Boehringer Ingelheim

  • GWP42003-P: GW Research

  • KarXT: Karuna Pharmaceuticals

  • Evenamide: Newron Pharmaceuticals

  • Paliperidone Palmitate 6-Month (PP6M): Janssen Pharmaceutical

Schizophrenia Market Drivers

  • Increasing Awareness

  • Growing Research and development

  • Pipeline Advancement

  • Long-acting Injectable Antipsychotics

Schizophrenia Market Barriers

  • Economic Burden

  • Significant Side Effects of Approved Therapy

  • Denial of illness

  • Co-occurring medical conditions

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

Schizophrenia Key Companies: Rovi Pharmaceuticals Laboratories, Minerva Neurosciences, BioXcel Therapeutics, Sunovion/PsychoGenics, Acadia Pharmaceuticals, Alkermes, Avineuro Pharmaceuticals, Boehringer Ingelheim, GW Research, Karuna Pharmaceuticals, Newron Pharmaceuticals, Janssen Pharmaceutical, among others. 

Schizophrenia Key Pipeline Therapies: Doria (risperidone ISM), Roluperidone, Dexmedetomidine (BXCL501), SEP363856, Pimavanserin, ALKS 3831, Avisetron (AVN-211), BI 409306, GWP42003-P, KarXT, Evenamide, Paliperidone Palmitate 6-Month (PP6M),and others.

Schizophrenia Segmentation: By Geography, Schizophrenia drugs

Analysis: Comparative and conjoint analysis of  Schizophrenia emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents 

1.

Key Insights

2.

Executive Summary of Schizophrenia

3.

Schizophrenia Market Overview at a Glance

4.

Disease Background and Overview: Schizophrenia

5.

Schizophrenia Case Reports

6.

Schizophrenia Epidemiology and Patient Population

7.

Schizophrenia United States Epidemiology

8.

Schizophrenia EU5 Epidemiology

9.

Schizophrenia Japan Epidemiology

10.

Schizophrenia Treatment

11.

Schizophrenia Unmet needs

12.

Schizophrenia Marketed Drugs

13.

Schizophrenia Emerging Drugs

14.

Key Endpoints

15.

Schizophrenia: 7MM Market Analysis

16.

Schizophrenia United States Market Outlook

17.

Schizophrenia EU-5 Market Outlook

18.

Schizophrenia Japan Market Outlook

19.

Schizophrenia Key Market Forecast Assumptions

20.

Schizophrenia Market Drivers

21.

Schizophrenia Market Barriers

22.

SWOT Analysis

23.

Schizophrenia Reimbursement and Market Access

24.

Appendix

25.

DelveInsight Capabilities

26.

Disclaimer

27.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Sciatica Market

Get comprehensive historical and forecast analysis of Sciatica Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kolon Life Science, Teijin America, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/